The Effect of Auditory Interventions on Anxiety and Agitation in People With Dementia
NCT ID: NCT05844241
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2023-05-08
2023-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Music and Theta Auditory Beat Stimulation (ABS)
Participants listen to 30 minutes of personalized music with theta auditory beat stimulation (ABS).
Music and Theta Auditory Beat Stimulation
Listening to music and ABS for 30 minutes.
Audiobooks
Participants listen to a 30-minute audiobook.
Audiobooks
Listening to audiobooks for 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Music and Theta Auditory Beat Stimulation
Listening to music and ABS for 30 minutes.
Audiobooks
Listening to audiobooks for 30 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Severe Tinnitus
* Hyperacusis
65 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lucid, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adiel Mallik, PhD
Role: PRINCIPAL_INVESTIGATOR
Lucid, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LUCID Therapeutics
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUC101A
Identifier Type: -
Identifier Source: org_study_id